First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - ScienceDirect

$ 16.00

4.7
(629)
In stock
Description

First-in-human study of the safety, pharmacokinetics, and

Suppressing fatty acid synthase by type I interferon and chemical

Acetyl-CoA metabolism as a therapeutic target for cancer

PDF) First-in-human study of the safety, pharmacokinetics, and

Targeting fatty acid uptake and metabolism in cancer cells: A

Acetyl-CoA metabolism as a therapeutic target for cancer

TVB-2640 (Denifanstat, Fatty Acid Synthase Inhibitor 2, FASN-IN-2

First-in-human study of the safety, pharmacokinetics, and

Frontiers First-In-Human Study to Assess the Safety

First-in-human study of the safety, pharmacokinetics, and

Pharmacokinetic behavior of ALT-801 and semaglutide in C57Bl/6J

Emerging roles of fatty acid metabolism in cancer and their

Emerging roles of fatty acid metabolism in cancer and their

FASN inhibitor TVB-3166 prevents S-acylation of the spike protein